Search

Your search keyword '"Tran, Hai T."' showing total 387 results
Start Over Author "Tran, Hai T."
387 results on '"Tran, Hai T."'

1. Enhancing NSCLC recurrence prediction with PET/CT habitat imaging, ctDNA, and integrative radiogenomics-blood insights

Author

Sujit, Sheeba J., Aminu, Muhammad, Karpinets, Tatiana V., Chen, Pingjun, Saad, Maliazurina B., Salehjahromi, Morteza, Boom, John D., Qayati, Mohamed, George, James M., Allen, Haley, Antonoff, Mara B., Hong, Lingzhi, Hu, Xin, Heeke, Simon, Tran, Hai T., Le, Xiuning, Elamin, Yasir Y., Altan, Mehmet, Vokes, Natalie I., Sheshadri, Ajay, Lin, Julie, Zhang, Jianhua, Lu, Yang, Behrens, Carmen, Godoy, Myrna C. B., Wu, Carol C., Chang, Joe Y., Chung, Caroline, Jaffray, David A., Wistuba, Ignacio I., Lee, J. Jack, Vaporciyan, Ara A., Gibbons, Don L., Heymach, John, Zhang, Jianjun, Cascone, Tina, and Wu, Jia

Published
2024
Full Text
View/download PDF

2. A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation

Author

Piha-Paul, Sarina A., Tseng, Chieh, Tran, Hai T., Gao, Meng, Karp, Daniel D., Subbiah, Vivek, Tsimberidou, Apostolia Maria, Kawedia, Jitesh D., Fu, Siqing, Pant, Shubham, Yap, Timothy A., Morris, Van K., Kee, Bryan K., Blum Murphy, Mariela, Lim, JoAnn, and Meric-Bernstam, Funda

Published
2023
Full Text
View/download PDF

4. Surgical approach does not influence changes in circulating immune cell populations following lung cancer resection

Author

Deboever, Nathaniel, McGrail, Daniel J., Lee, Younghee, Tran, Hai T., Mitchell, Kyle G., Antonoff, Mara B., Hofstetter, Wayne L., Mehran, Reza J., Rice, David C., Roth, Jack A., Swisher, Stephen G., Vaporciyan, Ara A., Walsh, Garrett L., Bernatchez, Chantale, Vailati Negrao, Marcelo, Zhang, Jianjun, Wistuba, Ignacio I., Heymach, John V., Cascone, Tina, Gibbons, Don L., Haymaker, Cara L., and Sepesi, Boris

Published
2022
Full Text
View/download PDF

6. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial

Author

Cascone, Tina, William, William N., Jr, Weissferdt, Annikka, Leung, Cheuk H., Lin, Heather Y., Pataer, Apar, Godoy, Myrna C. B., Carter, Brett W., Federico, Lorenzo, Reuben, Alexandre, Khan, Md Abdul Wadud, Dejima, Hitoshi, Francisco-Cruz, Alejandro, Parra, Edwin R., Solis, Luisa M., Fujimoto, Junya, and Tran, Hai T.

Subjects
Ipilimumab -- Testing, Neoadjuvant therapy -- Testing, Lung cancer, Non-small cell -- Drug therapy, Biological sciences, Health
Abstract

Ipilimumab improves clinical outcomes when combined with nivolumab in metastatic non-small cell lung cancer (NSCLC), but its efficacy and impact on the immune microenvironment in operable NSCLC remain unclear. We report the results of the phase 2 randomized NEOSTAR trial (NCT03158129) of neoadjuvant nivolumab or nivolumab + ipilimumab followed by surgery in 44 patients with operable NSCLC, using major pathologic response (MPR) as the primary endpoint. The MPR rate for each treatment arm was tested against historical controls of neoadjuvant chemotherapy. The nivolumab + ipilimumab arm met the prespecified primary endpoint threshold of 6 MPRs in 21 patients, achieving a 38% MPR rate (8/21). We observed a 22% MPR rate (5/23) in the nivolumab arm. In 37 patients resected on trial, nivolumab and nivolumab + ipilimumab produced MPR rates of 24% (5/21) and 50% (8/16), respectively. Compared with nivolumab, nivolumab + ipilimumab resulted in higher pathologic complete response rates (10% versus 38%), less viable tumor (median 50% versus 9%), and greater frequencies of effector, tissue-resident memory and effector memory T cells. Increased abundance of gut Ruminococcus and Akkermansia spp. was associated with MPR to dual therapy. Our data indicate that neoadjuvant nivolumab + ipilimumab-based therapy enhances pathologic responses, tumor immune infiltrates and immunologic memory, and merits further investigation in operable NSCLC. Neoadjuvant treatment with nivolumab plus ipilimumab is well tolerated and demonstrates clinical efficacy in patients with early stage lung cancer., Author(s): Tina Cascone [sup.1] , William N. William Jr [sup.1] [sup.15] , Annikka Weissferdt [sup.2] [sup.3] , Cheuk H. Leung [sup.4] , Heather Y. Lin [sup.4] , Apar Pataer [sup.3] [...]

Published
2021
Full Text
View/download PDF

8. Programmed Death-Ligand 1 Heterogeneity and Its Impact on Benefit From Immune Checkpoint Inhibitors in NSCLC

Author

Hong, Lingzhi, Negrao, Marcelo V., Dibaj, Seyedeh S., Chen, Runzhe, Reuben, Alexandre, Bohac, Jadi M., Liu, Xiaoke, Skoulidis, Ferdinandos, Gay, Carl M., Cascone, Tina, Mitchell, Kyle G., Tran, Hai T., Le, Xiuning, Byers, Lauren A., Sepesi, Boris, Altan, Mehmet, Elamin, Yasir Y., Fossella, Frank V., Kurie, Jonathan M., Lu, Charles, Mott, Frank E., Tsao, Anne S., Rinsurongkawong, Waree, Lewis, Jeff, Gibbons, Don L., Glisson, Bonnie S., Blumenschein, George R., Jr., Roarty, Emily B., Futreal, P. Andrew, Wistuba, Ignacio I., Roth, Jack A., Swisher, Stephen G., Papadimitrakopoulou, Vassiliki A., Heymach, John V., Lee, J. Jack, Simon, George R., and Zhang, Jianjun

Published
2020
Full Text
View/download PDF

11. Abstract A022: Dissecting patterns of small cell lung cancer evolution using deep whole genome sequencing of circulating tumor DNA

Author

Morris, Benjamin B., primary, Zhang, Zhihui, additional, Heeke, Simon, additional, Concannon, Kyle, additional, Zhang, Bingan, additional, Rinsurongkawong, Waree, additional, Rinsurongkawong, Vadeerat, additional, Lee, J. Jack, additional, Zhang, Jianjun, additional, Gibbons, Don L., additional, Vaporciyan, Ara A., additional, Gay, Carl M., additional, Tran, Hai T., additional, Heymach, John V., additional, Byers, Lauren A., additional, and Van Loo, Peter, additional

Published
2024
Full Text
View/download PDF

12. Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma

Author

Papadimitrakopoulou, Vasiliki A, Frank, Steven J, Cohen, Ezra W, Hirsch, Fred R, Myers, Jeffrey N, Heymach, John V, Lin, Heather, Tran, Hai T, Chen, Changhu R, Jimeno, Antonio, Nedzi, Lucien, Vasselli, Joseph R, Lowe, Elizabeth S, and Raben, David

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Orphan Drug, Clinical Research, Cancer, Rare Diseases, Dental/Oral and Craniofacial Disease, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Squamous Cell, Chemoradiotherapy, Cisplatin, Female, Head and Neck Neoplasms, Humans, Male, Maximum Tolerated Dose, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Quinazolines, Squamous Cell Carcinoma of Head and Neck, cisplatin, head and neck squamous cell cancer, radiation therapy, vandetanib, Dentistry, Otorhinolaryngology, Clinical sciences
Abstract

BackgroundVandetanib, added to cisplatin and radiation therapy (RT) overcomes chemoradiation therapy (CRT) and epidermal growth factor receptor (EGFR) inhibitor resistance in head and neck squamous cell carcinoma (HNSCC) lines and models.MethodsPatients with previously untreated HNSCC received vandetanib daily for 14 days (starting dose 100 mg) and then vandetanib + RT (2.2 Gy/day, 5 days/week) for 6 weeks (regimen 1) or vandetanib + RT (2 Gy/day, 5 days/week) + cisplatin (30 mg/m(2) weekly) for 7 weeks (regimen 2). The primary objective was the maximum tolerated dose (MTD) of vandetanib with RT +/- cisplatin.ResultsOf 33 treated patients, 30 completed therapy (regimen 1, n = 12; regimen 2, n = 18). MTD in regimen 2 was 100 mg (3 dose limiting toxicities [DLTs] at 200 mg), whereas regimen 1 was stopped because of poor recruitment (1 DLT at 200 mg). Most common grade ≥3 adverse events (AEs) were dysphagia (30%), stomatitis (33%), and mucosal inflammation (27%). Five patients discontinued vandetanib because of AEs.ConclusionVandetanib with CRT was feasible.

Published
2016

13. Distinct patterns of auto-reactive antibodies associated with organ-specific immune-related adverse events

Author

Altan, Mehmet, primary, Li, Quan-Zhen, additional, Wang, Qi, additional, Vokes, Natalie I., additional, Sheshadri, Ajay, additional, Gao, Jianjun, additional, Zhu, Chengsong, additional, Tran, Hai T., additional, Gandhi, Saumil, additional, Antonoff, Mara B., additional, Swisher, Stephen, additional, Wang, Jing, additional, Byers, Lauren A., additional, Abdel-Wahab, Noha, additional, Franco-Vega, Maria C., additional, Wang, Yinghong, additional, Lee, J. Jack, additional, Zhang, Jianjun, additional, and Heymach, John V., additional

Published
2023
Full Text
View/download PDF

14. Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations

Author

Lam, Vincent K., Tran, Hai T., Banks, Kimberly C., Lanman, Richard B., Rinsurongkawong, Waree, Peled, Nir, Lewis, Jeff, Lee, J. Jack, Roth, Jack, Roarty, Emily B., Swisher, Stephen, Talasaz, AmirAli, Futreal, P. Andrew, Papadimitrakopoulou, Vassiliki, Heymach, John V., and Zhang, Jianjun

Published
2019
Full Text
View/download PDF

15. Clinical Outcomes in Non–Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Author

Tran, Hai T., Lam, Vincent K., Elamin, Yasir Y., Hong, Lingzhi, Colen, Rivka, Elshafeey, Nabil A., Hassan, Islam S. A., Altan, Mehmet, Blumenschein, George R., Rinsurongkawong, Waree, Rivera, Melvin J., Vasquez, Mayra E., Carter, Brett W., Byers, Lauren E., Tsao, Anne S., Gibbons, Don L., Fossella, Frank, Glisson, Bonnie S., Zhang, Jianjun, and Heymach, John V.

Published
2021
Full Text
View/download PDF

16. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer

Author

Xiao, Guan-Yu, primary, Tan, Xiaochao, additional, Rodriguez, Bertha L., additional, Gibbons, Don L., additional, Wang, Shike, additional, Wu, Chao, additional, Liu, Xin, additional, Yu, Jiang, additional, Vasquez, Mayra E., additional, Tran, Hai T., additional, Xu, Jun, additional, Russell, William K., additional, Haymaker, Cara, additional, Lee, Younghee, additional, Zhang, Jianjun, additional, Solis, Luisa, additional, Wistuba, Ignacio I., additional, and Kurie, Jonathan M., additional

Published
2023
Full Text
View/download PDF

17. Data from High-Dose Fenretinide in Oral Leukoplakia

Author

William, William N., primary, Lee, J. Jack, primary, Lippman, Scott M., primary, Martin, Jack W., primary, Chakravarti, Nitin, primary, Tran, Hai T., primary, Sabichi, Anita L., primary, Kim, Edward S., primary, Feng, Lei, primary, Lotan, Reuben, primary, and Papadimitrakopoulou, Vassiliki A., primary

Published
2023
Full Text
View/download PDF

18. Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Author

Patel, Sonia A., primary, Nilsson, Monique B., primary, Yang, Yan, primary, Le, Xiuning, primary, Tran, Hai T., primary, Elamin, Yasir Y., primary, Yu, Xiaoxing, primary, Zhang, Fahao, primary, Poteete, Alissa, primary, Ren, Xiaoyang, primary, Shen, Li, primary, Wang, Jing, primary, Moghaddam, Seyed Javad, primary, Cascone, Tina, primary, Curran, Michael, primary, Gibbons, Don L., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

19. Data from The BATTLE Trial: Personalizing Therapy for Lung Cancer

Author

Kim, Edward S., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Blumenschein, George R., primary, Tsao, Anne, primary, Stewart, David J., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Alden, Christine M., primary, Liu, Suyu, primary, Tang, Ximing, primary, Khuri, Fadlo R., primary, Tran, Hai T., primary, Johnson, Bruce E., primary, Heymach, John V., primary, Mao, Li, primary, Fossella, Frank, primary, Kies, Merrill S., primary, Papadimitrakopoulou, Vassiliki, primary, Davis, Suzanne E., primary, Lippman, Scott M., primary, and Hong, Waun K., primary

Published
2023
Full Text
View/download PDF

22. Data from Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer

Author

Heymach, John V., primary, Shackleford, Terry J., primary, Tran, Hai T., primary, Yoo, Suk-Young, primary, Do, Kim-Anh, primary, Wergin, Melanie, primary, Saintigny, Pierre, primary, Vollmer, Robin T., primary, Polascik, Thomas J., primary, Snyder, Denise C., primary, Ruffin, Mack T., primary, Yan, Shaoyu, primary, Dewhirst, Mark, primary, Kunnumakkara, Ajaikumar B., primary, Aggarwal, Bharat B., primary, and Demark-Wahnefried, Wendy, primary

Published
2023
Full Text
View/download PDF

23. Supplementary Tables 1-3 and Table A-1, Figure 1, Appendix and Information from The BATTLE Trial: Personalizing Therapy for Lung Cancer

Author

Kim, Edward S., primary, Herbst, Roy S., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Blumenschein, George R., primary, Tsao, Anne, primary, Stewart, David J., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Alden, Christine M., primary, Liu, Suyu, primary, Tang, Ximing, primary, Khuri, Fadlo R., primary, Tran, Hai T., primary, Johnson, Bruce E., primary, Heymach, John V., primary, Mao, Li, primary, Fossella, Frank, primary, Kies, Merrill S., primary, Papadimitrakopoulou, Vassiliki, primary, Davis, Suzanne E., primary, Lippman, Scott M., primary, and Hong, Waun K., primary

Published
2023
Full Text
View/download PDF

24. Supplementary Tables 2-4 from Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer

Author

Heymach, John V., primary, Shackleford, Terry J., primary, Tran, Hai T., primary, Yoo, Suk-Young, primary, Do, Kim-Anh, primary, Wergin, Melanie, primary, Saintigny, Pierre, primary, Vollmer, Robin T., primary, Polascik, Thomas J., primary, Snyder, Denise C., primary, Ruffin, Mack T., primary, Yan, Shaoyu, primary, Dewhirst, Mark, primary, Kunnumakkara, Ajaikumar B., primary, Aggarwal, Bharat B., primary, and Demark-Wahnefried, Wendy, primary

Published
2023
Full Text
View/download PDF

25. Supplementary Table 1 from Effect of Low-Fat Diets on Plasma Levels of NF-κB–Regulated Inflammatory Cytokines and Angiogenic Factors in Men with Prostate Cancer

Author

Heymach, John V., primary, Shackleford, Terry J., primary, Tran, Hai T., primary, Yoo, Suk-Young, primary, Do, Kim-Anh, primary, Wergin, Melanie, primary, Saintigny, Pierre, primary, Vollmer, Robin T., primary, Polascik, Thomas J., primary, Snyder, Denise C., primary, Ruffin, Mack T., primary, Yan, Shaoyu, primary, Dewhirst, Mark, primary, Kunnumakkara, Ajaikumar B., primary, Aggarwal, Bharat B., primary, and Demark-Wahnefried, Wendy, primary

Published
2023
Full Text
View/download PDF

26. Data from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Author

Patel, Sonia A., primary, Nilsson, Monique B., primary, Yang, Yan, primary, Le, Xiuning, primary, Tran, Hai T., primary, Elamin, Yasir Y., primary, Yu, Xiaoxing, primary, Zhang, Fahao, primary, Poteete, Alissa, primary, Ren, Xiaoyang, primary, Shen, Li, primary, Wang, Jing, primary, Moghaddam, Seyed Javad, primary, Cascone, Tina, primary, Curran, Michael, primary, Gibbons, Don L., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

28. Supplementary tables from Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Author

Sundaresan, Tilak K., primary, Sequist, Lecia V., primary, Heymach, John V., primary, Riely, Gregory J., primary, Jänne, Pasi A., primary, Koch, Walter H., primary, Sullivan, James P., primary, Fox, Douglas B., primary, Maher, Robert, primary, Muzikansky, Alona, primary, Webb, Andrew, primary, Tran, Hai T., primary, Giri, Uma, primary, Fleisher, Martin, primary, Yu, Helena A., primary, Wei, Wen, primary, Johnson, Bruce E., primary, Barber, Thomas A., primary, Walsh, John R., primary, Engelman, Jeffrey A., primary, Stott, Shannon L., primary, Kapur, Ravi, primary, Maheswaran, Shyamala, primary, Toner, Mehmet, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

29. Supplementary Fig. S1 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells

Author

Zinner, Ralph G., primary, Barrett, Brittany L., primary, Popova, Elmira, primary, Damien, Paul, primary, Volgin, Andrei Y., primary, Gelovani, Juri G., primary, Lotan, Reuben, primary, Tran, Hai T., primary, Pisano, Claudio, primary, Mills, Gordon B., primary, Mao, Li, primary, Hong, Waun K., primary, Lippman, Scott M., primary, and Miller, John H., primary

Published
2023
Full Text
View/download PDF

30. Data Supplement from Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial

Author

Blumenschein, George R., primary, Saintigny, Pierre, primary, Liu, Suyu, primary, Kim, Edward S., primary, Tsao, Anne S., primary, Herbst, Roy S., primary, Alden, Christine, primary, Lee, J. Jack, primary, Tang, Ximing, primary, Stewart, David J., primary, Kies, Merrill S., primary, Fossella, Frank V., primary, Tran, Hai T., primary, Mao, L., primary, Hicks, Marshall E., primary, Erasmus, Jeremy, primary, Gupta, Sanjay, primary, Girard, Luc, primary, Peyton, Michael, primary, Diao, Lixia, primary, Wang, Jing, primary, Davis, Suzanne E., primary, Minna, John D., primary, Wistuba, Ignacio, primary, Hong, Waun K., primary, Heymach, John V., primary, and Lippman, Scott M., primary

Published
2023
Full Text
View/download PDF

31. Supplementary figures and tables from Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

Author

Chen, Runzhe, primary, Lee, Won-Chul, primary, Fujimoto, Junya, primary, Li, Jun, primary, Hu, Xin, primary, Mehran, Reza, primary, Rice, David, primary, Swisher, Stephen G., primary, Sepesi, Boris, primary, Tran, Hai T., primary, Chow, Chi-Wan, primary, Little, Latasha D., primary, Gumbs, Curtis, primary, Haymaker, Cara, primary, Heymach, John V., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Futreal, P. Andrew, primary, Zhang, Jianhua, primary, Reuben, Alexandre, primary, Tsao, Anne S., primary, and Zhang, Jianjun, primary

Published
2023
Full Text
View/download PDF

32. Supplementary Table S1 from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells

Author

Zinner, Ralph G., primary, Barrett, Brittany L., primary, Popova, Elmira, primary, Damien, Paul, primary, Volgin, Andrei Y., primary, Gelovani, Juri G., primary, Lotan, Reuben, primary, Tran, Hai T., primary, Pisano, Claudio, primary, Mills, Gordon B., primary, Mao, Li, primary, Hong, Waun K., primary, Lippman, Scott M., primary, and Miller, John H., primary

Published
2023
Full Text
View/download PDF

33. Supplementary Methods from Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells

Author

Zinner, Ralph G., primary, Barrett, Brittany L., primary, Popova, Elmira, primary, Damien, Paul, primary, Volgin, Andrei Y., primary, Gelovani, Juri G., primary, Lotan, Reuben, primary, Tran, Hai T., primary, Pisano, Claudio, primary, Mills, Gordon B., primary, Mao, Li, primary, Hong, Waun K., primary, Lippman, Scott M., primary, and Miller, John H., primary

Published
2023
Full Text
View/download PDF

34. Supplementary figures from Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

Author

Sundaresan, Tilak K., primary, Sequist, Lecia V., primary, Heymach, John V., primary, Riely, Gregory J., primary, Jänne, Pasi A., primary, Koch, Walter H., primary, Sullivan, James P., primary, Fox, Douglas B., primary, Maher, Robert, primary, Muzikansky, Alona, primary, Webb, Andrew, primary, Tran, Hai T., primary, Giri, Uma, primary, Fleisher, Martin, primary, Yu, Helena A., primary, Wei, Wen, primary, Johnson, Bruce E., primary, Barber, Thomas A., primary, Walsh, John R., primary, Engelman, Jeffrey A., primary, Stott, Shannon L., primary, Kapur, Ravi, primary, Maheswaran, Shyamala, primary, Toner, Mehmet, primary, and Haber, Daniel A., primary

Published
2023
Full Text
View/download PDF

35. Supplemental Figures and tables from The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non–Small Cell Lung Cancer

Author

Cascone, Tina, primary, Xu, Li, primary, Lin, Heather Y., primary, Liu, Wenbin, primary, Tran, Hai T., primary, Liu, Yuan, primary, Howells, Kathryn, primary, Haddad, Vincent, primary, Hanrahan, Emer, primary, Nilsson, Monique B., primary, Cortez, Maria A., primary, Giri, Uma, primary, Kadara, Humam, primary, Saigal, Babita, primary, Park, Yun-Yong, primary, Peng, Weiyi, primary, Lee, Ju-Seog, primary, Ryan, Anderson J., primary, Jüergensmeier, Juliane M., primary, Herbst, Roy S., primary, Wang, Jing, primary, Langley, Robert R., primary, Wistuba, Ignacio I., primary, Lee, Jack J., primary, and Heymach, John V., primary

Published
2023
Full Text
View/download PDF

36. Supplementary Data from Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment

Author

Chen, Runzhe, primary, Lee, Won-Chul, primary, Fujimoto, Junya, primary, Li, Jun, primary, Hu, Xin, primary, Mehran, Reza, primary, Rice, David, primary, Swisher, Stephen G., primary, Sepesi, Boris, primary, Tran, Hai T., primary, Chow, Chi-Wan, primary, Little, Latasha D., primary, Gumbs, Curtis, primary, Haymaker, Cara, primary, Heymach, John V., primary, Wistuba, Ignacio I., primary, Lee, J. Jack, primary, Futreal, P. Andrew, primary, Zhang, Jianhua, primary, Reuben, Alexandre, primary, Tsao, Anne S., primary, and Zhang, Jianjun, primary

Published
2023
Full Text
View/download PDF

39. IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Author

Patel, Sonia A., primary, Nilsson, Monique B., additional, Yang, Yan, additional, Le, Xiuning, additional, Tran, Hai T., additional, Elamin, Yasir Y., additional, Yu, Xiaoxing, additional, Zhang, Fahao, additional, Poteete, Alissa, additional, Ren, Xiaoyang, additional, Shen, Li, additional, Wang, Jing, additional, Moghaddam, Seyed Javad, additional, Cascone, Tina, additional, Curran, Michael, additional, Gibbons, Don L., additional, and Heymach, John V., additional

Published
2023
Full Text
View/download PDF

41. Abstract P078: Cancer cell derived extracellular vesicles convey protein signatures of small cell lung carcinoma

Author

Vykoukal, Jody, primary, Kato, Taketo, additional, Katayama, Hiroyuki, additional, Stewart, Allison, additional, Irajizad, Ehsan, additional, Cai, Yining, additional, Hsiao, Fu-Chung, additional, Dennison, Jennifer B., additional, Ostrin, Edwin J., additional, Tran, Hai T., additional, Gay, Carl M., additional, Byers, Lauren A., additional, Fahrmann, Johannes F., additional, and Hanash, Samir M., additional

Published
2023
Full Text
View/download PDF

45. Inhibition of the Phosphatidylinositol-3 Kinase Pathway Using Bimiralisib in Loss-of-Function NOTCH1-Mutant Head and Neck Cancer

Author

Johnson, Faye M, primary, Janku, Filip, additional, Gouda, Mohamed A, additional, Tran, Hai T, additional, Kawedia, Jitesh D, additional, Schmitz, Debora, additional, Streefkerk, Hendrik, additional, Lee, J Jack, additional, Andersen, Clark R, additional, Deng, Defeng, additional, Rawal, Seema, additional, Shah, Pooja A, additional, El-Naggar, Adel K, additional, Johnson, Jason M, additional, and Frederick, Mitchell J, additional

Published
2022
Full Text
View/download PDF

47. EMT activates exocytotic Rabs to coordinate invasion and immunosuppression in lung cancer.

Author

Guan-Yu Xiao, Xiaochao Tan, Rodriguez, Bertha L., Gibbons, Don L., Shike Wang, Chao Wu, Xin Liu, Jiang Yu, Vasquez, Mayra E., Tran, Hai T., Jun Xu, Russell, William K., Haymaker, Cara, Younghee Lee, Jianjun Zhang, Solis, Luisa, Wistub, Ignacio I., and Kurie, Jonathan M.

Subjects
GUANINE nucleotide exchange factors, LUNG cancer, T-cell exhaustion, FOCAL adhesions, IMMUNOSUPPRESSION
Abstract

Epithelial-tomesenchymal transition (EMT) underlies immunosuppression, drug resistance, and metastasis in epithelial malignancies. However, the way in which EMT orchestrates disparate biological processes remains unclear. Here, we identify an EMTactivated vesicular trafficking network that coordinates promigratory focal adhesion dynamics with an immunosuppressive secretory program in lung adenocarcinoma (LUAD). The EMT-activating transcription factor ZEB1 drives exocytotic vesicular trafficking by relieving Rab6A, Rab8A, and guanine nucleotide exchange factors from miR-148a-dependent silencing, thereby facilitating MMP14-dependent focal adhesion turnover in LUAD cells and autotaxin-mediated CD8+ T cell exhaustion, indicating that cellintrinsic and extrinsic processes are linked through a microRNA that coordinates vesicular trafficking networks. Blockade of ZEB1-dependent secretion reactivates antitumor immunity and negates resistance to PD-L1 immune checkpoint blockade, an important clinical problem in LUAD. Thus, EMT activates exocytotic Rabs to drive a secretory program that promotes invasion and immunosuppression in LUAD. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

48. Results of a phase 1b study of osimertinib plus sapanisertib or alisertib for osimertinib-resistant, EGFR-mutant non–small cell lung cancer (NSCLC).

Author

Elamin, Yasir Y, primary, Negrao, Marcelo Vailati, additional, Fossella, Frank V., additional, Byers, Lauren Averett, additional, Zhang, Jianjun, additional, Gay, Carl Michael, additional, Tu, Janet Chen, additional, Pozadzides, Jenny Vu, additional, Tran, Hai T., additional, Lu, Charles, additional, Feng, Lei, additional, Spelman, Amy R., additional, Blumenschein, George R., additional, Tsao, Anne S., additional, and Heymach, John, additional

Published
2022
Full Text
View/download PDF

49. Auto-reactive antibodies as predictive markers for immune checkpoint–induced pneumonitis.

Author

Altan, Mehmet, primary, Wang, Qi, additional, Li, Quan-Zhen, additional, Zhu, Chengsong, additional, Tran, Hai T., additional, Sheshadri, Ajay, additional, Gandhi, Saumil, additional, Antonoff, Mara, additional, Swisher, Stephen, additional, Vokes, Natalie I, additional, Spelman, Amy R., additional, Lee, J. Jack, additional, Zhang, Jianjun, additional, and Heymach, John, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results